Co-Inhibition of PARP and STAT3 as a Promising Approach for Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a highly aggressive subtype known for its rapid metastatic potential. Despite its severity, treatment options for TNBC remain limited. Olaparib, an FDA-approved PARP inhibitor, has been used to treat germline <i>BRCA</i>-mutated TNBC in both metast...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/15/7/1035 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|